KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Current Deferred Revenue: 2009-2025

Historic Current Deferred Revenue for Arbutus Biopharma (ABUS) over the last 10 years, with Mar 2025 value amounting to $6.8 million.

  • Arbutus Biopharma's Current Deferred Revenue fell 41.47% to $6.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $6.8 million, marking a year-over-year decrease of 41.47%. This contributed to the annual value of $7.6 million for FY2024, which is 35.79% down from last year.
  • Per Arbutus Biopharma's latest filing, its Current Deferred Revenue stood at $6.8 million for Q1 2025, which was down 10.73% from $7.6 million recorded in Q4 2024.
  • Over the past 5 years, Arbutus Biopharma's Current Deferred Revenue peaked at $23.3 million during Q1 2022, and registered a low of $6.8 million during Q1 2025.
  • Over the past 3 years, Arbutus Biopharma's median Current Deferred Revenue value was $11.5 million (recorded in 2024), while the average stood at $11.3 million.
  • Data for Arbutus Biopharma's Current Deferred Revenue shows a maximum YoY tumbled of 41.47% (in 2025) over the last 5 years.
  • Over the past 4 years, Arbutus Biopharma's Current Deferred Revenue (Quarterly) stood at $16.5 million in 2022, then fell by 28.35% to $11.8 million in 2023, then slumped by 35.79% to $7.6 million in 2024, then tumbled by 41.47% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q1 2025, $7.6 million for Q4 2024, and $10.9 million during Q3 2024.